Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Abstract excerpt

Abstract Background Until today, adult and pediatric clinical trials investigating single-agent or combinatorial HDAC inhibitors including vorinostat in solid tumors have largely failed to demonstrate efficacy. These results may in part be explained by data from preclinical models showing significant activity only at higher concentrations compared to those achieved with current dosing regimens. In the current...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Angiogenesis and VEGF in Cancer
• Share to Histone Deacetylase Inhibitors Research
• Share to Peptidase Inhibition and Analysis